Compare Medpace Holdings Inc (MEDP) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nuscale Power Corporation — how do they compare? Medpace Holdings Inc trades at $528.16 (market cap $15.18B), while Nuscale Power Corporation trades at $8.71 (market cap $3.01B). The key difference: Medpace Holdings Inc is far larger — about 5× Nuscale Power Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| MEDP | SMR | |
|---|---|---|
Market Cap | $15.18B | $3.01B |
Sector | Technology | Utilities |
52-Week High | $620.59 | $53.43 |
52-Week Low | $393.42 | $7.64 |
Enterprise Value | $14.65B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company shows severe fundamental challenges with negative net income margins exceeding -2,000% and consecutive earnings misses. Despite these losses, analyst consensus remains optimistic with a $12.25 price target representing 54% upside potential, driven by nuclear energy's long-term prospects and the company's first-mover advantage in small modular reactors.
The stock presents a high-risk, high-reward opportunity. While current financials are deeply concerning with massive losses and negative cash flow, the potential nuclear energy renaissance and SMR's regulatory approvals offer substantial upside if commercialization succeeds. Investors face significant execution risk as the company burns cash while attempting to secure its first commercial reactor sale.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
